Boston scientific receives fda approval for therasphere™ y-90 glass microspheres

Marlborough, mass., march 18, 2021 /prnewswire/ -- boston scientific corporation (nyse: bsx) announced it has received u.s. food and drug administration (fda) approval of the therasphere™ y-90 glass microspheres, developed for the treatment of patients with hepatocellular carcinoma (hcc).
BSX Ratings Summary
BSX Quant Ranking